JP2023540888A5 - - Google Patents

Info

Publication number
JP2023540888A5
JP2023540888A5 JP2023512109A JP2023512109A JP2023540888A5 JP 2023540888 A5 JP2023540888 A5 JP 2023540888A5 JP 2023512109 A JP2023512109 A JP 2023512109A JP 2023512109 A JP2023512109 A JP 2023512109A JP 2023540888 A5 JP2023540888 A5 JP 2023540888A5
Authority
JP
Japan
Prior art keywords
hla
mutation
cells
amino acid
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540888A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000556 external-priority patent/WO2022038411A1/en
Publication of JP2023540888A publication Critical patent/JP2023540888A/ja
Publication of JP2023540888A5 publication Critical patent/JP2023540888A5/ja
Pending legal-status Critical Current

Links

JP2023512109A 2020-08-19 2021-08-18 非天然の改変Ｆｃ受容体に特異的に結合する、ヒトＩｇＧの非天然の改変Ｆｃ領域 Pending JP2023540888A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067629P 2020-08-19 2020-08-19
US63/067,629 2020-08-19
PCT/IB2021/000556 WO2022038411A1 (en) 2020-08-19 2021-08-18 Human non-naturally occurring modified fc region of igg specifically binding to non-naturally occurring modified fc receptor

Publications (2)

Publication Number Publication Date
JP2023540888A JP2023540888A (ja) 2023-09-27
JP2023540888A5 true JP2023540888A5 (enExample) 2024-08-23

Family

ID=78085961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512109A Pending JP2023540888A (ja) 2020-08-19 2021-08-18 非天然の改変Ｆｃ受容体に特異的に結合する、ヒトＩｇＧの非天然の改変Ｆｃ領域

Country Status (11)

Country Link
US (1) US20230303658A1 (enExample)
EP (1) EP4200325A1 (enExample)
JP (1) JP2023540888A (enExample)
KR (1) KR20230052279A (enExample)
CN (1) CN116322749A (enExample)
AU (1) AU2021328717A1 (enExample)
BR (1) BR112023003036A2 (enExample)
CA (1) CA3189553A1 (enExample)
IL (1) IL300484A (enExample)
MX (1) MX2023002013A (enExample)
WO (1) WO2022038411A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204016D0 (en) * 2022-03-22 2022-05-04 Ucl Business Plc Affinity chromatography ligands for antibody glycovariant separation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) * 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
WO2007127936A2 (en) * 2006-04-27 2007-11-08 Pikamab, Inc. Methods and compositions for antibody therapy
JP2013528357A (ja) * 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
EP3693017A1 (en) 2010-12-14 2020-08-12 University of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
JP2014513948A (ja) 2011-04-20 2014-06-19 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション β２ミクログロブリン欠損細胞
PL2838548T3 (pl) 2012-04-17 2024-02-05 University Of Washington Through Its Center For Commercialization Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2017091546A1 (en) 2015-11-23 2017-06-01 Trustees Of Boston University Methods and compositions relating to chimeric antigen receptors
WO2017161333A1 (en) 2016-03-18 2017-09-21 Unum Therapeutics Modified chimeric receptors and uses thereof in immune therapy

Similar Documents

Publication Publication Date Title
JP7531925B2 (ja) Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用
Crowley et al. Mind the gap: how interspecies variability in IgG and its receptors may complicate comparisons of human and non-human primate effector function
JP2024144548A5 (enExample)
JP2022162047A5 (enExample)
ES2692206T3 (es) Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades
ES2423993T3 (es) Proteínas HLA-G y usos farmacéuticos de las mismas
AU2016363025A1 (en) Modified chimeric receptors and related compositions and methods
KR102133887B1 (ko) 면역글로불린 Fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물
IL101147A (en) Redirection of cellular immunity by receptor chimeras
KR102263643B1 (ko) 면역 관련 질환의 예방 또는 치료용 조성물
US12152065B2 (en) T cell receptor for identifying AFP antigen
JP2022522404A5 (enExample)
HUE025294T2 (en) New chemokine-binding polypeptides that are able to inhibit the process of autoimmunity, inflammation and cancer
WO2019091347A1 (zh) 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途
Leiden et al. The complete primary structure of the T-cell receptor genes from an alloreactive cytotoxic human T-lymphocyte clone
CN111655845A (zh) 代谢调节剂在肿瘤微环境中的表达以改善肿瘤的治疗
JPH05507911A (ja) 多発性硬化症ｔ細胞受容体
KR20220052987A (ko) Ebv 유래 항원에 특이적인 tcr 작제물
CN119895039A (zh) 突变多肽、包含所述突变多肽的组合物及其用途
CN114555815A (zh) T细胞受体及其使用方法
EP3496749B9 (en) Mhc class ia open conformers
US20240285737A1 (en) Improved methods of treatment using immunogenic peptides
CN114450414A (zh) T细胞受体及其使用方法
JP2025504968A (ja) サイトメガロウイルス抗原を標的とするｔｃｒおよびそれを発現するｔ細胞ならびに使用
WO2018071405A1 (en) Vectors and vaccine cells for immunity against zika virus